No Data
Shuoyao Holdings (688197.SH): Adjusting the development strategy of BTK inhibitor SY-1530.
As of November 6, Kang Long Hui announced that several BTK inhibitors have been approved for marketing worldwide. There are already 5 drugs approved for marketing domestically, with several more in clinical research pipeline. The company has conducted a cautious evaluation of the market competition pattern, development progress, expected scale of future registration clinical trials, market share, and commercial returns of candidate drug SY-1530, and based on the manpower, material, and financial needs of key clinical trials and registration application work for other core candidate drugs, the company has decided to adjust the follow-up development strategy for SY-1530.
First Pharmaceutical Holdings (Beijing) Co., Ltd. Report for the Third Quarter of 2024
Express News | ShuoYao Holdings: The new drug application for Kangtai Nilotinib granules has been accepted.
Express News | Star Market Market Summary: Biopharmaceuticals and lithium battery sectors performed poorly, while semiconductor sector had mixed gains and losses.
Shouyao Holdings (688197): Outstanding independent research and development capabilities, leading the development of small molecule targeted drugs.
Coreview Pharma Group released its 2024 interim report, showing a certain degree of decrease in revenue compared to the same period last year. This is due to the fact that the sales revenue of the company's R&D products has not been realized yet, and current revenue comes from collaborative R&D income. R&D expenses are increasing along with new drug R&D projects and
Shouyao Holdings: Summary of the semi-annual report of Beijing Pharmaceutical Holdings Co., Ltd. in 2024
No Data
No Data